Company intelligence / Profile preview

MapKure, LLC

Cambridge, Massachusetts, United Statesir.beigene.com ↗

Ownership: Private
Development stage: Phase 1

Overview

MapKure is conducting Phase 1a/1b studies of BGB-3245 (brimarafenib), a selective RAF dimer inhibitor, in patients with advanced or refractory solid tumors harboring MAPK pathway aberrations. Early clinical data has shown promising activity, supporting advancement into selected expansion cohorts. A Phase 1/2a combination study of BGB-3245 and mirdametinib is also ongoing.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Brimarafenib

Discontinued

Partnerships

BeiGeneSpringWorks TherapeuticsPersonalis

Beyond the preview

Go deeper on MapKure, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MapKure, LLC.

Explore the full profile